No abstract

Background: The Chimeric antigen receptor T cell (CAR-T cell) is a kind of effector T cell that detects and kills cancer cells without the need for major histocompatibility complex components. The entire process of creating CAR-T cells is not well known. Acute lymphoblastic leukemia, chronic lymphocytic leukaemia, lymphoma, and multiple myeloma are among the haematological cancers for which the CAR-T cell has been employed. Objectives: Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). Data Sources: Electronic articles and Journal articles about role of Cart-T Cell therapy in hematological malignancy. Study Selection: This essay was containing data from many resources such as Google scholar, Elsevier, PMC, PubMed, England Journal, and Blood Journal to facilitate achieving the aim. Data Extraction: If the studies did not fulfil the inclusion criteria, they were excluded. Study quality assessment included ethical approval was gained, eligibility criteria specified, adequate information and defined assessment measures. Recent Findings: Fourth-generation CARs include the combination of second-generation CARs with an additional element, such as the tumor-killing cytokine IL-12. This type of CAR has improved tumor eradication by releasing cytokines into the tumor microenvironment and recruiting immune cells without prior conditioning. In addition, it has been used to treat virus infections, metabolic disorders and autoimmune diseases in addition to cancers. Conclusion: CAR T cell therapy has brought a new hope for the treatment of malignant hematological diseases such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM).